We need your help! If you've ever found our data helpful, please take our impact survey (15 min). Your replies will help keep the data flowing to the scientific community. Please Click here for Survey


Dataset Information


Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).

ABSTRACT: To assess baricitinib on patient-reported outcomes (PROs) in patients with moderately to severely active rheumatoid arthritis, who had insufficient response or intolerance to ?1 tumour necrosis factor inhibitors (TNFis) or other biological disease-modifying antirheumatic drugs (bDMARDs).In this double-blind phase III study, patients were randomised to once-daily placebo or baricitinib 2 or 4?mg for 24?weeks. PROs included the Short Form-36, EuroQol 5-D, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient's Global Assessment of Disease Activity (PtGA), patient's assessment of pain, duration of morning joint stiffness (MJS) and Work Productivity and Activity Impairment Questionnaire-Rheumatoid Arthritis. Treatment comparisons were performed with logistic regression for categorical measures or analysis of covariance for continuous variables.527 patients were randomised (placebo, 176; baricitinib 2?mg, 174; baricitinib 4?mg, 177). Both baricitinib-treated groups showed statistically significant improvements versus placebo in most PROs. Improvements were generally more rapid and of greater magnitude for patients receiving baricitinib 4?mg than 2?mg and were maintained to week 24. At week 24, more baricitinib-treated patients versus placebo-treated patients reported normal physical functioning (HAQ-DI <0.5; p?0.001), reductions in fatigue (FACIT-F ?3.56; p?0.05), improvements in PtGA (p?0.001) and pain (p?0.001) and reductions in duration of MJS (p<0.01).Baricitinib improved most PROs through 24?weeks compared with placebo in this study of treatment-refractory patients with previously inadequate responses to bDMARDs, including at least one TNFi. PRO results aligned with clinical efficacy data for baricitinib.NCT01721044; Results.


PROVIDER: S-EPMC5530360 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5372156 | BioStudies
2017-01-01 | S-EPMC5705852 | BioStudies
2017-01-01 | S-EPMC5604362 | BioStudies
2017-01-01 | S-EPMC5413813 | BioStudies
2015-01-01 | S-EPMC4632359 | BioStudies
2019-01-01 | S-EPMC6902348 | BioStudies
2016-01-01 | S-EPMC5051508 | BioStudies
2020-01-01 | S-EPMC7566034 | BioStudies
2017-01-01 | S-EPMC5353328 | BioStudies
2016-01-01 | S-EPMC5012017 | BioStudies